Rehan Khan Explores Clopidogrel
Rehan Khan, Hospital Pharmacist and Manager Auctus Hospital, shared on LinkedIn:
”Day 2/365 – Medicine of the Day: CLOPIDOGREL
One-Sentence Definition
Clopidogrel is an antiplatelet drug used to prevent blood clot formation in patients with cardiovascular and cerebrovascular diseases.
Pharmacological Overview
Drug class: Antiplatelet agent (P2Y₁₂ receptor inhibitor)
Drug type: Prodrug
Primary role: Prevention of arterial thrombosis
Therapeutic Uses
- Acute Coronary Syndrome (ACS)
- Post–myocardial infarction (MI)
- Stroke and TIA prevention
- After coronary stent placement
- Alternative in aspirin intolerance
Mechanism of Action (MOA)
- Inhibits ADP (P2Y₁₂) receptors on platelets
- Prevents activation of GPIIb/IIIa complex
- Lowers Platelet aggregation
- Effect lasts for platelet lifespan (7–10 days)
Common Dose
- Maintenance dose: 75 mg once daily
- Loading dose (ACS/PCI): 300–600 mg stat
Key Adverse Effects
Bleeding (most common)
Gastrointestinal upset
Rare: Thrombotic thrombocytopenic purpura (TTP)
Clinical Pearl
Clopidogrel is a prodrug—its efficacy depends on liver enzyme activation (CYP2C19).
HISTORY OF CLOPIDOGREL
1980s: Development of thienopyridine antiplatelets
1997: Clopidogrel approved for clinical use
CAPRIE trial: Showed superiority over aspirin in reducing ischemic events
Modern era: Backbone of dual antiplatelet therapy (DAPT) with aspirin
Why Clopidogrel Matters
- Essential in cardiology and interventional practice
- Life-saving in stent patients
- WHO essential cardiovascular medicine
Widely used globally in ACS protocols”
Stay updated with Hemostasis Today.
-
Oct 4, 2026, 13:04World Federation of Hemophilia Invites Global Community to GPAS 2026
-
Oct 4, 2026, 12:57Tooth Extraction in Patients with Haemophilia – RPTH Journal
-
Oct 4, 2026, 12:36Maia Meier: Advancing Hemophilia Care in Nepal – Project Elevate Her Visits Civil Service Hospital
-
Oct 4, 2026, 12:30Shailaja Kota Amplifies World Inherited Blood Disorders Month and Global Action Network’s Call to Action
-
Oct 4, 2026, 12:21Davide Pallucci: How Altered Platelet Metabolism Can Drive Changes in their Reactivity in Human and Mouse MASLD
-
Oct 4, 2026, 11:02Stimuli-Induced Remodeling of the Platelet Lipidome in Pulmonary Embolism – ESC
-
Oct 4, 2026, 10:45Join the Bleeding Disorders Advocacy Network! – HFA
-
Oct 4, 2026, 06:12David McIntosh: 900 Plasma Donations One Patient One Lifeline
-
Oct 4, 2026, 06:00Aadil Sheikh: Menopausal Hormone Therapy and Thrombosis Rethinking Route Dose and Risk